News
Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...
On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...
Marstacimab is a tissue factor pathway inhibitor antagonist approved under the brand name Hympavzi.
13d
Zacks.com on MSNPFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets GoalPfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with ...
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
This release contains forward-looking information about HYMPAVZI™ (marstacimab), an anti-tissue factor pathway inhibitor, including its potential benefits and plans to discuss the Phase 3 BASIS ...
Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...
Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for ...
The tissue factor pathway inhibitor (TFPI) antagonist, given as a subcutaneous injection, has been cleared to prevent or reduce bleeding episodes in patients aged 12 years and older with ...
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
NEW YORK, NY, USA I June 26, 2025 I Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results